Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT
· Real-Time Price · USD
7.29
0.13 (1.82%)
At close: Oct 03, 2025, 3:59 PM
7.30
0.14%
After-hours: Oct 03, 2025, 07:59 PM EDT
1.82% (1D)
| Bid | 7 |
| Market Cap | 226M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.38M |
| EPS (ttm) | -1.89 |
| PE Ratio (ttm) | -3.86 |
| Forward PE | -3.69 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.5 |
| Volume | 316,451 |
| Avg. Volume (20D) | 638,026 |
| Open | 7.29 |
| Previous Close | 7.16 |
| Day's Range | 7.15 - 7.55 |
| 52-Week Range | 1.73 - 11.41 |
| Beta | 3.27 |
| Ex-Dividend Date | n/a |
About SGMT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SGMT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SGMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+6.36%
Sagimet Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
4 months ago
+12.4%
Sagimet Biosciences shares are trading higher after the company announced its Phase 3 Denifanstat acne therapy clinical trial met all primary and secondary endpoints.
1 month ago · seekingalpha.com
Sagimet Gains Momentum As FDA Eases Path For MASH Drug DevelopmentSagimet Biosciences offers a unique play in MASH with Denifanstat, a FASN inhibitor showing both fat reduction and fibrosis regression in Phase 2b. The FDA's acceptance of non-invasive trial endpoints...
